Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial
Importance
Level 1
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES